Upgrade for detailed insurance, legislation, and other documents analytics for individual cases; real-time analysis of the datasets from your EHR, CRM, ERP, or other software; and more Enterprise Features.
ALL MEDICAL CODES IN CATEGORY Cancer and Vision Associated Drugs
2025 HCPCS code Q5134
Natalizumab-sztn biosimilar, Tyruko®, 1 mg
2025 HCPCS code Q5128
Represents 0.1 mg of ranibizumab-eqrn (Cimerli™), a biosimilar to Lucentis, used to treat various eye conditions by inhibiting vascular endothelial growth factor (VEGF).
2025 HCPCS code Q5118
Biosimilar bevacizumab-bvzr (Zirabev), 10 mg injection for intravenous infusion.
2025 HCPCS code Q5119
Rituximab-pvvr injection, 10 mg
2025 HCPCS code Q5120
This code represents 0.5 mg of Ziextenzo (pegfilgrastim-bmez), a biosimilar to pegfilgrastim, used to reduce infection risk in cancer patients receiving myelosuppressive chemotherapy.
This HCPCS code represents 10 mg of rituximab-arrx (Riabni), a rituximab biosimilar, administered intravenously for treating non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
2025 HCPCS code Q5124
This HCPCS code represents the supply of 0.1 mg of ranibizumab-nuna (Byooviz), a biosimilar drug used to treat various eye conditions.
2025 HCPCS code Q5115
Tiêm, rituximab-abbs, tương tự sinh học, (Truxima), 10 mg.
Injection, pegfilgrastim-fpgk (Stimufend), biosimilar, 0.5 mg; a leukocyte growth factor used to reduce infection risk in patients undergoing myelosuppressive chemotherapy.
Continue with Personal Account
Thank you for exploring iFrame ♥ Please subscribe for unlimited access to our top-tier AI model, which directly supports our dedicated knowledge creators maintaining an ad-free internet experience.